STOCK TITAN

Forte Biosciences Inc - FBRX STOCK NEWS

Welcome to our dedicated news page for Forte Biosciences (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Forte Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Forte Biosciences's position in the market.

Rhea-AI Summary
Forte Biosciences, Inc. (NASDAQ: FBRX) announces 2023 results, highlighting the advancement of FB-102 into clinical trials. Research and development expenses increased to $21.9 million, with net losses per share at ($1.00). Forte ended 2023 with $37.1 million in cash and approximately 36.3 million shares outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
Rhea-AI Summary
Forte Biosciences, Inc. (NASDAQ: FBRX) issues 25,000 shares of common stock as an equity inducement award to a new non-executive employee, in accordance with NASDAQ Listing Rule 5635(c)(4). The award will vest over four years, subject to continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Forte Biosciences, Inc. (NASDAQ: FBRX) announced third quarter 2023 results, highlighting progress on FB-102 and plans for human clinical trials. The company raised $25.0 million in a private placement and reported increased research and development expenses. Forte ended the quarter with approximately $46.2 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.51%
Tags
Rhea-AI Summary
Camac Partners and ATG Capital respond to misrepresentations in Forte Biosciences' recent presentation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
-
Rhea-AI Summary
Forte Biosciences announces key R&D updates for FB-102, a potential treatment for autoimmune diseases. FB-102 has demonstrated best-in-class activity in graft versus host disease (GvHD) and shows potential in other indications. The company plans to advance FB-102 into clinical trials in 2024. Forte Biosciences has closed a $25 million financing round with support from top-tier institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
management
Forte Biosciences Inc

Nasdaq:FBRX

FBRX Rankings

FBRX Stock Data

26.32M
22.01M
10.92%
56.17%
0.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Torrance

About FBRX

we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he